Enterprise Value

166.7M

Cash

88.89M

Avg Qtr Burn

-7.959M

Short % of Float

0.22%

Insider Ownership

0.00%

Institutional Own.

0.62%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
LUMOXITI Details
Hairy Cell Leukemia

Approved

Quarterly sales

Monalizumab + durvalumab Details
Solid tumor/s, Non-small cell lung carcinoma, Cancer

Phase 3

Update

Phase 2

Data readout

Phase 2

Data readout

Lacutamab (IPH4102) Details
Lymphoma, Cancer, Mycosis fungoides

Phase 2

Data readout

Lacutamab (IPH4102) Details
Cancer, Lymphoma, Peripheral T cell cancer

Phase 2

Data readout

Lacutamab (IPH4102) Details
Lymphoma, Sezary syndrome, Cancer

Phase 2

Data readout

IPH5201 Details
Cancer, Lung cancer

Phase 2

Initiation

IPH6401 / SAR’514 Details
Cancer, relapsed or refractory light chain amyloidosis, Multiple myeloma

Phase 1/2

Data readout

IPH6101/SAR’579 Details
Cancer, B-cell acute lymphoblastic leukemia, Relapsed/refractory acute myeloid leukemia

Phase 1/2

Update

IPH5301 (anti-CD73) Details
Cancer, Solid tumor/s

Phase 1

Data readout

Monalizumab (anti-NKG2A) Details
Head and neck cancer, Head and neck squamous cell carcinoma, Cancer

Failed

Discontinued

Avdoralimab (IPH5401) Details
Bullous pemphigoid , Skin disease/disorder

Failed

Discontinued